Equities research analysts at Cantor Fitzgerald decreased their FY2025 earnings estimates for Biogen in a research note ...

Biogen (NASDAQ:BIIB – Get Free Report)‘s stock had its “hold” rating reiterated by equities research analysts at Needham & ...

Among small-molecule drugs, upadacitinib and deucravacitinib demonstrate the best efficacy for treatment of psoriatic ...

Humira (adalimumab) has dominated in the inflammatory diseases including psoriasis and rheumatoid arthritis markets for a decade, and AbbVie needs newer drugs that outperform it and rivals in each ...

AbbVie made a change atop its board of directors, naming CEO Robert Michael as chairman on Friday morning. The pharma giant announced that Michael will succeed Richard A. Gonzalez, the former CEO of ...

chronic psoriasis, hidradenitis suppurativa, and juvenile idiopathic arthritis. Humira is patent protected in the US until 2023, where the majority of its sales are based.

We recently compiled a list of the Top 10 Stocks to Buy According to Lee Munder Capital Group. In this article, we are going ...

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...

The Department of Veterans Affairs (VA) saved $67 million in 2023 through its strong adoption of biosimilars to curb the high ...